Antitumor agents. 293. Nontoxic dimethyl-4,4′-dimethoxy-5,6,5′, 6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate (DDB) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5413-5424

  Hung, Hsin Yi ^a   Ohkoshi, Emika ^a   Goto, Masuo ^b   Bastow, Kenneth F ^a   Nakagawa Goto, Kyoko ^a   Lee, Kuo Hsiung ^a,c  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

(4,4 DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(3,4 DIMETHOXYBENZOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2 'DIYL)BIS(METHYLENE)BIS(2,2 DIMETHYLPROPANOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(2 METHYLBUTANOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(2 METHYLPENTANOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(2 METHYLPROPANOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(2,3,4 TRIMETHOXYBENZOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(3 METHYLBUT 2 ENOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(3 METHYLBUTANOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(4 CYANOBENZOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(4 METHOXYBENZOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(4 METHYLBENZOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(4 NITROBENZOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(BUT 2 ENOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)BIS(HEXA 2,4 DIENOATE); (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)DIACETATE; (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)DIBENZOATE; (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)DIBUTYRATE; (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)DICYCLOHEXANECARBOXYLATE; (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)DICYCLOPENTANECARBOXYLATE; (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)DIDODECANOATE; (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)DIPENTANOATE; (4,4' DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DIYL)BIS(METHYLENE)DIPROPIONATE; ANTINEOPLASTIC AGENT; DIMETHYL 4,4'DIMETHOXY 5,6,5',6' DIMETHYLENEDIOXYBIPHENYL 2,2' DICARBOXYLATE; DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIZATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; NASOPHARYNX CARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ESTERS; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP; VINCRISTINE;

EID: 84862285321     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300378k     Document Type: Article

References (25)

1. Perez-Sayans, M.; Somoza-Martin, J. M.; Barros-Angueira, F.; Diz, P. G.; Rey, J. M.; Garcia-Garcia, A. Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar ATPases Cancer Lett. 2010, 295, 135-143
2. Zhou, T.; Shi, Q.; Bastow, K. F.; Lee, K. H. Antitumor agents. 286. Design, synthesis, and structure-activity relationships of 3′ R,4′ R -disubstituted-2′,2′-dimethyldihydropyrano[2,3- f ]chromone (DSP) analogues as potent chemosensitizers to overcome multidrug resistance J. Med. Chem. 2010, 53, 8700-8708
3. Fodale, V.; Pierobon, M.; Liotta, L.; Petricoin, E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J. 2011, 17, 89-95
4. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Oncogene 2010, 29, 4741-4751
5. Torres-Romero, D.; Munoz-Martinez, F.; Jimenez, I. A.; Castanys, S.; Gamarro, F.; Bazzocchi, I. L. Novel dihydro-β-agarofuran sesquiterpenes as potent modulators of human P-glycoprotein dependent multidrug resistance Org. Biomol. Chem. 2009, 7, 5166-5172
6. Das, S. G.; Doshi, J. M.; Tian, D.; Addo, S. N.; Srinivasan, B.; Hermanson, D. L.; Xing, C. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3- carboxylate (sha 14-1) and its analogues J. Med. Chem. 2009, 52, 5937-5949
7. Mor, G.; Montagna, M. K.; Alvero, A. B. Modulation of apoptosis to reverse chemoresistance Methods Mol. Biol. 2008, 414, 1-12
8. Zhang, P. Y.; Wong, I. L.; Yan, C. S.; Zhang, X. Y.; Jiang, T.; Chow, L. M.; Wan, S. B. Design and syntheses of permethyl ningalin B analogues: potent multidrug resistance (MDR) reversal agents of cancer cells J. Med. Chem. 2010, 53, 5108-5120
9. Robey, R. W.; Shukla, S.; Finley, E. M.; Oldham, R. K.; Barnett, D.; Ambudkar, S. V.; Fojo, T.; Bates, S. E. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1 Biochem. Pharmacol. 2008, 75, 1302-1312
10. Sun, M.; Xu, X.; Lu, Q.; Pan, Q.; Hu, X.; Schisandrin, B. A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1 Cancer Lett. 2007, 246, 300-307
11. Qiangrong, P.; Wang, T.; Lu, Q.; Hu, X.; Schisandrin, B. A novel inhibitor of P-glycoprotein Biochem. Biophys. Res. Commun. 2005, 335, 406-411
12. Li, L.; Pan, Q.; Sun, M.; Lu, Q.; Hu, X. Dibenzocyclooctadiene lignans - A class of novel inhibitors of multidrug resistance-associated protein 1 Life Sci. 2007, 80, 741-748
13. Sun, H.; Liu, G. T. Chemopreventive effect of dimethyl dicarboxylate biphenyl on malignant transformation of WB-F344 rat liver epithelial cells Acta Pharmacol. Sin. 2005, 26, 1339-1344
14. Jin, J.; Sun, H.; Wei, H.; Liu, G. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis Invest. New Drugs 2007, 25, 95-105
15. Yu, H. Q.; Yang, X. Y.; Zhang, Y. X.; Shi, J. Z. Biphenyl-dimethyl dicarboxylate in treating and preventing hepatitis due to drug poisoning Chin. Med. J. (Beijing, China, Engl. Ed.) 1987, 100, 122-123
16. Huber, R.; Hockenjos, B.; Blum, H. E. DDB treatment of patients with chronic hepatitis Hepatology 2004, 39, 1732-1733
17. Zhu, B.; Liu, G. T.; Zhao, Y. M.; Wu, R. S.; Strada, S. J. Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2 Cancer Biol. Ther. 2006, 5, 536-543
18. Zhu, B.; Liu, G. T.; Wu, R. S.; Strada, S. J. Chemoprevention of bicyclol against hepatic preneoplastic lesions Cancer Biol. Ther. 2006, 5, 1665-1673
19. Xie, L.; Xie, J. X.; Kashiwada, Y.; Cosentino, L. M.; Liu, S. H.; Pai, R. B.; Cheng, Y. C.; Lee, K. H. Anti-AIDS (acquired immune deficiency syndrome) agents. 17. New brominated hexahydroxybiphenyl derivatives as potent anti-HIV agents J. Med. Chem. 1995, 38, 3003-3008
20. Molander, G. A.; George, K. M.; Monovich, L. G. Total synthesis of (+)-isoschizandrin utilizing a samarium(II) iodide-promoted 8-endo ketyl-olefin cyclization J. Org. Chem. 2003, 68, 9533-9540
21. Soai, K.; Yokoyama, S.; Mochida, K. Reduction of symmetric and mixed anhydrides of carboxylic acids by sodium borohydride with dropwise addition of methanol Synthesis 1987, 647-648
22. Calcabrini, A.; Meschini, S.; Stringaro, A.; Cianfriglia, M.; Arancia, G.; Molinari, A. Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells Histochem. J. 2000, 32, 599-606
23. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 2009, 323, 1718-1722
24. Pajeva, I. K.; Wiese, M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis) J. Med. Chem. 2002, 45, 5671-5686
25. Pajeva, I. K.; Globisch, C.; Wiese, M. Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors ChemMedChem 2009, 4, 1883-1896